# Profusa, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Profusa, Inc.). ## Overview Profusa, Inc. is a U.S.-based medical technology company focused on developing and commercializing implantable biosensor products for continuous biochemical monitoring. Its core platform includes the Lumee Oxygen and Lumee Glucose devices, and it also operates through a Singapore subsidiary created to support development and commercialization in Asia Pacific. ## Products & services • Implantable biosensor platform for continuous monitoring • Lumee Oxygen device under development • Lumee Glucose device under development • Product development, manufacturing, and commercialization support • Asia Pacific joint venture structure for regional expansion - **Implantable biosensors** (70%) — Core sensor products designed to measure biochemical signals continuously in the body. - **Glucose monitoring devices** (15%) — Lumee Glucose products intended for glucose sensing and diabetes-related monitoring. - **Oxygen monitoring devices** (15%) — Lumee Oxygen products intended for oxygen sensing and related clinical monitoring. - Implantable biosensor platform for continuous monitoring - Lumee Oxygen device under development - Lumee Glucose device under development - Product development, manufacturing, and commercialization support - Asia Pacific joint venture structure for regional expansion ## Customers Profusa’s customers are primarily healthcare and life-science users that need continuous physiological monitoring, including clinical, research, and commercialization partners. The company’s products are designed for applications where implantable sensing can provide more persistent data than intermittent testing. Its Asia Pacific structure also suggests future collaboration with regional commercial partners for product development and market access. - **Clinical and healthcare users** (primary) — Hospitals, clinicians, and care providers that would use continuous monitoring data for patient management. - **Research and development partners** (secondary) — Organizations collaborating on device validation, product development, and clinical evidence generation. - **Commercialization partners** (primary) — Third parties that help develop, manufacture, or distribute Lumee products in target markets. - **Asia Pacific joint venture counterparties** (secondary) — Regional partners involved in the planned APAC joint venture for development and commercialization. - Clinical users seeking continuous biochemical monitoring - Healthcare partners evaluating implantable sensing applications - Research and development collaborators - Commercialization partners for regional product rollout - Potential diabetes and oxygen-monitoring end users ## Geography Profusa is headquartered in the United States and operates through a U.S. parent structure with a wholly owned Singapore subsidiary for Asia Pacific activities. The Singapore entity was created to support development, manufacturing, and commercialization of Lumee products with a regional partner, indicating an intended footprint beyond the U.S. Geography matters because regulatory approvals, manufacturing coordination, and commercialization partnerships may differ by market. - **United States** (80%) — Primary corporate and operating base - **Asia Pacific** (20%) — Planned regional commercialization through Singapore APAC subsidiary - Headquartered in the United States - Singapore subsidiary supports Asia Pacific expansion - APAC structure is intended for regional development and commercialization - U.S. operations remain central to corporate and R&D activity - Future market access depends on local regulatory and partner execution ## Strategy Profusa’s strategy centers on advancing Lumee Oxygen and Lumee Glucose through regulatory, manufacturing, and commercialization milestones. The company is also building a regional partnership structure in Asia Pacific to support development and market entry, while preserving flexibility to raise additional capital as needed. - **Regulatory approval and product readiness** (short-term) — The devices cannot be commercialized at scale without required approvals and validation. - **Commercialization build-out** (medium-term) — The company needs manufacturing, sales, and marketing infrastructure to convert development assets into revenue. - **Asia Pacific partnership execution** (medium-term) — The Singapore subsidiary and planned joint venture are intended to extend market reach and localize execution. - Advance Lumee Oxygen and Lumee Glucose toward commercialization - Secure regulatory approvals needed for product launch - Build manufacturing and scale-up capabilities - Use APAC joint venture to support regional expansion - Maintain financing flexibility for development and rollout ## Risks Profusa faces the typical risks of a development-stage medical device company: regulatory uncertainty, product development risk, manufacturing scale-up risk, and dependence on external financing. The reports also highlight public-company compliance costs, going-concern sensitivity, and fair-value volatility from convertible instruments and warrants, which can materially affect reported results. - **Regulatory approval delays** [high] — The Lumee products require approvals before broad commercialization, and delays would push out revenue generation. - **Financing and going-concern dependence** [critical] — The company may need additional equity or debt to fund R&D, manufacturing, and commercialization. - **Manufacturing and scale-up execution** [high] — Medical device commercialization depends on reliable production, quality control, and supply chain readiness. - **Valuation volatility from complex instruments** [medium] — Convertible notes, warrant liabilities, and related-party loans are remeasured at fair value. - Regulatory approval risk could delay or block commercialization - Development and manufacturing execution risk for Lumee products - Additional financing may be needed to fund operations and growth - Fair value changes in warrants and convertible debt can swing earnings - Public company compliance adds cost and operational complexity ## Accounting Profusa’s reporting is heavily influenced by fair-value accounting for warrants, convertible notes, and related-party financing instruments, which can create non-cash gains and losses each period. As a development-stage company, it also has limited revenue history, so operating results can be highly sensitive to R&D spending, grant revenue recognition, and transaction-related costs around the business combination. - **Warrant liabilities** — Non-cash gains or losses in other income/expense - **Convertible promissory note valuation** — Fair value changes can materially affect reported results - **Related-party convertible loan** — Quarterly earnings sensitivity to valuation assumptions - **Government grant revenue** — Comparability across periods is limited - **Business combination accounting** — Period-to-period comparability and capital structure analysis - Fair value remeasurement of warrants affects periodic earnings - Convertible note valuation uses unobservable inputs and estimates - Related-party convertible loan is measured at fair value - Government grant revenue can be episodic and non-recurring - Business combination accounting affects capital structure and comparability --- *Last updated: 2026-04-29T04:49:49.416174+00:00*